News

PALO ALTO, CA, USA, November 14, 2023 – Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations with its academic partners is to identify academic research programs targeting important unmet medical needs and to advance their commercialization in companies it launches.

Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system

No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma

To help get more girls interested in STEM, let’s spotlight inspiring women in science! A great example is Yvonne Chen, who is doing life-saving research. She is co-founder of ImmPACT Bio, which is based in Camarillo, California. The biotech company recently received positive results in its Phase 1 clinical study in relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (R/R B-cell NHL).

Read the Entire Article Here